SRPT Sarepta Therapeutics,, Inc. Common Stock
XNAS
17.68
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
SRPT
$17.68
—
What changed
Recent filings, trades and movesKey stats
$17.68
- 52-Week Range
- $14.68 – $24.68
- YTD
- -17.01%
- IV Rank (30D)
- 35.91
- Straddle Price
- $3.32
- P/C Vol Ratio
- 1.28
- Market Cap
- $1.9B
- Open
- $17.97
- Day Range
- $17.01 – $18.05
- Volume
- 1,085,001
- Prev Close
- $17.82
Fair Value
MODEL: LONG
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.90% |
| Beta vs SPY | 1.01 |
| Cost of Equity (CAPM) | 10.46% (VRP-adj) |
| WACC | 8.90% |
| Volatility Risk Premium | +46.7pp (IV − HV30), ERP adj +50bps |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +0.5% |
| DCF Horizon | 5 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.00 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $0.1B |
| Return on Equity (TTM) | -8.9% |
| Book / Price | 81.3% — banking bias active (P/B is primary) |
| Gross Margin (TTM) | 59.1% |
| FCF Margin (TTM) | 4.1% |
| Debt / Equity | 0.55 |
| Quality Score | 1/6 — cyclical/struggling (5y DCF) |
| Market-Implied Growth | +14.4% (reverse-DCF on current price) |
| SMA 50 | $19.13 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $18.12 |
| Bollinger Width / SMA20 | 17.4% (drives anchor stability) |
| Net Debt | $0.3B |
| Market Cap | $2B |
Peers used for multiples: BIIB, NBIX, TMDX
(filtered from 8 ETF-co-members; sector bias active)
60-Day Conviction
61%
20-Day Fair Value
≈ by Dec 8, 2026
$17.78
α +0.0%
rank 73%
conviction
1%
40-Day Fair Value
≈ by Jan 6, 2027
$18.32
α +3.0%
rank 86%
conviction
80%
60-Day Fair Value
≈ by Feb 4, 2027
$18.22
α +2.5%
rank 84%
conviction
61%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | $8.76 | 14% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 23.0× · 3 peers |
| Peer EV/EBITDA | n/a | 0% | median 22.0× · 3 peers |
| Peer P/B | $60.43 | 11% | median 4.2× · 3 peers |
| Peer P/S | $67.36 | 11% | median 3.6× · 3 peers |
| Market Anchor (SMA50) | $19.13 | 36% | stability 63% (BB-width) |
| Options Expected (B-L 30d) | $17.91 | 28% | 21 strikes · skew +0.14 |
As of 2026-11-09 · updated
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $1.9B
- Employees
- 835
- List Date
- 1997-06-04
- CIK
- 0000873303
- Last Earnings
- Nov 5 after close · +1.4% vs ±7.7% expected
- Headquarters
- Cambridge, MA
- Homepage
- https://www.sarepta.com
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare d…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | -45.91% | -20.85% | 0.10% | 23.68% | -8.36% | -4.55% | -9.31% |
| Feb | -3.26% | 3.18% | -0.19% | 4.13% | -6.20% | -19.11% | -3.57% |
| Mar | -14.36% | 2.76% | -5.36% | 0.61% | -36.95% | 33.33% | -3.33% |
| Apr | -7.05% | -12.40% | -10.75% | -1.36% | 0.79% | -5.65% | -6.07% |
| May | -1.89% | -1.30% | -1.21% | -0.79% | -40.11% | -16.85% | -10.36% |
| Jun | 2.75% | 3.25% | -7.85% | 27.18% | -54.69% | 2.04% | -4.55% |
| Jul | -13.40% | 22.77% | -4.49% | -9.26% | -7.28% | -18.71% | -5.06% |
| Aug | 13.89% | 19.48% | 12.54% | -5.71% | 14.39% | 32.43% | 14.50% |
| Sep | 16.58% | 0.42% | -1.05% | -7.56% | 6.11% | -14.58% | -0.01% |
| Oct | -17.62% | 3.71% | -43.24% | 3.00% | 24.28% | 5.98% | -3.98% |
| Nov | 0.94% | 7.65% | 6.22% | 8.15% | -12.72% | -2.95%* | 1.21% |
| Dec | 9.56% | 5.37% | 14.20% | -4.97% | 9.13% | -- | 6.66% |
| Total | -56.01% | 29.82% | -43.74% | 35.02% | -80.25% | -22.06% | -22.87% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $18.13
SMA 50: $19.07
SMA 200: $18.63
Current: $17.73
EMA 12: $18.21
EMA 26: $18.32
MACD: -0.1074 | Signal: -0.0318
BEARISH
ADX (14): 12.11
RANGE
+DI: 20.31
−DI: 25.87
Momentum Oscillators
RSI (14): 45.49
NEUTRAL
Stoch %K: 23.53
Stoch %D: 38.30
Williams %R: -73.05
Volume & Volatility
BB Upper: $19.68
BB Lower: $16.58
NEUTRAL
OBV: -93,878,050
Vol SMA 20: 2,380,265
Vol ROC: -21.02%
ATR: $0.99
True Range: $1.04
HV 20: 62.0%
HV 30: 54.0%
HV 60: 64.1%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-11-08T00:00:00 – 2026-11-06T00:00:00
AI Analysis
Written before SRPT’s Nov 5 earnings report, so it doesn’t reflect the results.
Here is my comprehensive stock analysis report for SRPT:
Executive Summary
Overall Assessment: BEARISH (Confidence Level: 7/10)
Key Drivers: High volatility, mixed technical signals, negative news sentiment
Primary Risks: Earnings miss, regulatory issues, high beta
Recent News Sentiment Impact: Negative headlines from The Motley Fool outweigh positive sentiments from other sources.
Technical Analysis
Trend Direction: Short-term (1-4 weeks): BEARISH Medium-term (1-3 months): NEUTRAL Long-term (3-12 months): BULLISH
Support/Resistance Levels:
- Upper: $20.99
- Middle: $17.95
- Lower: $14.91
Momentum Signals: RSI interpretation: Overbought (>70) MACD signal: Bullish, but histogram is overbought Bollinger Bands position: Squeeze, breakout imminent
Volume Analysis:
- Volume SMA 20: 3005166.94 ( decreasing trend)
- On-Balance Volume (OBV): -77412925.66 (bearish)
- Volume Rate of Change: 214.35% (volatile)
News & Sentiment Analysis
Recent Headlines Summary: Mixed news sentiment with two negative and four positive headlines
Sentiment Assessment: NEGATIVE (average sentiment from recent headlines)
Catalyst Identification: No clear catalysts, but earnings potential could drive price action
Market Narrative: Technical signals indicate a potential breakout or mean reversion, which could be influenced by mixed news sentiment.
Risk & Volatility Assessment
Risk Interpretation: High risk due to high beta and volatility
Volatility Regime: Current vs historical volatility levels - SRPT is more volatile than usual
Options Market Signals: IV rank: 18.2% (Low) - shows if volatility is historically high/low Current IV: 99.8% - indicating high implied volatility Expected Move: $3.72 (29 DTE), 7-DTE: $2.30 - options market pricing a potential move
Downside Protection:
- Support levels: $14.91 and below
- Risk management considerations: Stop-loss levels and position sizing
Market Context & Positioning
Sector Performance: Relative strength vs sector/market - SRPT underperforms the biotech sector
Institutional Activity: Volume patterns suggesting institutional interest - however, recent volume is decreasing
Correlation Analysis: How stock moves relative to market (R-squared interpretation) - SRPT has a moderate correlation with the market
Relative Valuation: Position within trading range - SRPT's price action could be influenced by its position within the trading range.
Key Levels & Action Items
Critical Price Levels: Support levels at $14.91 and below, resistance at $20.99
Breakout/Breakdown Levels: Technical levels that could trigger significant moves - above $17.95 or below $14.91
Time-Sensitive Catalysts: Earnings dates, FDA approvals, product launches - potential catalysts that could drive price action
Risk Management: Stop-loss levels and position sizing considerations - consider reducing position size or adjusting stop-loss levels based on volatility.
Note: This report is a comprehensive analysis of the provided stock data. The objective assessment is BEARISH due to high volatility, mixed technical signals, and negative news sentiment. The key drivers are earnings miss, regulatory issues, and high beta.
Generated
News
All SRPT news →
Gene therapy demand stabilizes while siRNA readouts and FDA talks loom ahead.
Earnings History
9 of 12 under expected move
Avg Expected Move
8.87%
Avg Actual Move
8.28%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2021-01-11 | After-Close | 9.53% | 2.76% | 0.29x | Within |
| 2021-10-15 | After-Close | 4.62% | 3.53% | 0.76x | Within |
| 2022-01-10 | After-Close | 10.87% | 0.25% | 0.02x | Within |
| 2023-01-09 | After-Close | 5.16% | 1.36% | 0.26x | Within |
| 2024-01-08 | After-Close | 6.09% | 16.72% | 2.75x | Exceeded |
| 2025-02-26 | After-Close | 8.38% | 3.56% | 0.42x | Within |
| 2025-07-16 | After-Close | 5.85% | 19.53% | 3.34x | Exceeded |
| 2025-11-03 | After-Close | 20.65% | 33.74% | 1.63x | Exceeded |
| 2026-01-12 | After-Close | 8.28% | 1.51% | 0.18x | Within |
| 2026-05-06 | After-Close | 9.77% | 9.68% | 0.99x | Within |
| 2026-08-05 | After-Close | 9.57% | 5.34% | 0.56x | Within |
| 2026-11-05 | After-Close | 7.68% | 1.42% | 0.18x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
SRPT Options Activity & IV Rank
SRPT IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 78.2%
7-DTE IV: 92.1%
Expected Move: $3.32
7-DTE Move: $1.15
Days to Exp: 32 (2026-12-11)
Options Flow · All expiries
Call Volume: 3,026
Put Volume: 3,863
P/C Volume: 1.277
NEUTRAL
Call OI: 75,866
Put OI: 50,783
P/C OI: 0.669
Total OI: 126,649
ATM Options Pricing
ATM Call: $1.27
ATM Put: $2.05
Call %: 7.2%
Put %: 11.6%
Chain Summary
Chain Volume: 6,889
Chain OI: 126,649
Last Updated: 11/9/2026
Spread Scanner
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Scanning bull put, bear call, iron condor and calendar spreads…
Dealer Positioning
TYPICAL γ
Estimated net dealer gamma is at the 50th percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
50%
vs own history
GEX tilt
+0.25
OI-weighted, today
Vanna tilt
+0.34
δ-sensitivity to IV
Charm tilt
-0.47
δ-decay vs time
Vanna tilt +0.34: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.47: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 41 ATM contracts, 16k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
80%
+13.8
pts
EXTREME
ATM 93.2% / Wing 107.0%
30 DTE / 10d
—
—
pts
EXTREME
ATM 78.5% / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Loading the implied volatility surface…
Volatility Smile
Loading the implied volatility smile…
IV Rank (7 DTE)48.2MediumNov 9
IV Rank (30 DTE)35.9MediumNov 9
Straddle Price (30 DTE)$3.32Nov 9
Beta Analysis
Risk Metrics
Beta: 1.6946
Alpha: 3.47%
Correlation: 0.3305
R-Squared: 10.9%
Stock Volatility: 70.5%
Market Volatility: 13.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own SRPT
6 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Millennium Management Hedge fund Izzy Englander | $21.4M | #1080 of 3716 | -2.3% | 13F | |
| Renaissance Technologies Hedge fund Jim Simons | $20.2M | #698 of 3138 | -32.7% | 13F | |
| Point72 Hedge fund Steve Cohen | $9.2M | #784 of 1945 | new | 13F | |
| Oaktree Capital Asset manager Howard Marks | $6.3M | #92 of 130 | new | 13F | |
| Bridgewater Associates Hedge fund Ray Dalio | $2.7M | #624 of 997 | +13.2% | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $93K | #3022 of 4729 | +1.3% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
SRPT Institutional Ownership (13F)
Filings for 2026-06-30 · 127 already for 2026-09-30
? 13F Guide
Diluted shares outstanding: 106,926,000 (as of 2026-06-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
16 filers$139.99M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Citadel Advisors LLC Custodian | $71.18M | 50.85% | 2026-06-30 |
| 2 | Susquehanna International Group, LLP Custodian | $36.18M | 25.84% | 2026-06-30 |
| 3 | Caption Management, LLC | $11.46M | 8.18% | 2026-06-30 |
| 4 | GROUP ONE TRADING LLC Custodian | $6.78M | 4.84% | 2026-06-30 |
| 5 | Simplex Trading, LLC Custodian | $3.20M | 2.28% | 2026-09-30 |
| 6 | IMC-Chicago, LLC Custodian | $2.06M | 1.47% | 2026-09-30 |
| 7 | Barclays PLC Custodian | $2.00M | 1.43% | 2026-09-30 |
| 8 | Jane Street Group, LLC Custodian | $1.65M | 1.18% | 2026-06-30 |
| 9 | Walleye Capital LLC | $1.55M | 1.11% | 2026-06-30 |
| 10 | CAPITAL FUND MANAGEMENT S.A. | $1.35M | 0.97% | 2026-06-30 |
| 11 | Hudson Bay Capital Management LP | $1.08M | 0.77% | 2026-06-30 |
| 12 | D. E. Shaw & Co., Inc. Custodian | $539.10K | 0.39% | 2026-06-30 |
| 13 | Citigroup Inc. Custodian | $437.28K | 0.31% | 2026-09-30 |
| 14 | J. Goldman & Co LP | $404.32K | 0.29% | 2026-06-30 |
| 15 | Raiffeisen Bank International AG | $93.75K | 0.07% | 2026-09-30 |
| 16 | LMR Partners LLP | $32.35K | 0.02% | 2026-06-30 |
16 filers$174.92M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | LMR Partners LLP | $75.06M | 42.91% | 2026-06-30 |
| 2 | Susquehanna International Group, LLP Custodian | $50.47M | 28.85% | 2026-06-30 |
| 3 | Citadel Advisors LLC Custodian | $12.06M | 6.89% | 2026-06-30 |
| 4 | WHITEBOX ADVISORS LLC | $11.57M | 6.61% | 2026-06-30 |
| 5 | Balyasny Asset Management L.P. | $5.39M | 3.08% | 2026-06-30 |
| 6 | NOMURA HOLDINGS INC | $4.31M | 2.46% | 2026-06-30 |
| 7 | Simplex Trading, LLC Custodian | $3.87M | 2.21% | 2026-09-30 |
| 8 | Caption Management, LLC | $2.70M | 1.54% | 2026-06-30 |
| 9 | Barclays PLC Custodian | $2.19M | 1.25% | 2026-09-30 |
| 10 | IMC-Chicago, LLC Custodian | $2.01M | 1.15% | 2026-09-30 |
| 11 | Jane Street Group, LLC Custodian | $1.95M | 1.12% | 2026-06-30 |
| 12 | GROUP ONE TRADING LLC Custodian | $1.57M | 0.90% | 2026-06-30 |
| 13 | SIG BROKERAGE, LP | $673.88K | 0.39% | 2026-06-30 |
| 14 | WOLVERINE ASSET MANAGEMENT LLC | $497.41K | 0.28% | 2026-09-30 |
| 15 | Citigroup Inc. Custodian | $437.28K | 0.25% | 2026-09-30 |
| 16 | Walleye Capital LLC | $167.12K | 0.10% | 2026-06-30 |
SRPT Insider Trading (Form 4)
Latest: 2026-09-08Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-09-08 | Ryan Ho-Yan Wong | Chief Financial Officer | Tax (F) | −13,272 | $22.22 | -$294.9K | EDGAR |
| 2026-09-08 | Ian Michael Estepan | Chief Operating Officer | Tax (F) | −24,799 | $22.22 | -$551.0K | EDGAR |
| 2026-09-08 | Cristin Rothfuss | EVP, General Counsel | Tax (F) | −22,025 | $22.22 | -$489.4K | EDGAR |
| 2026-09-08 | Louise Rodino-Klapac | President, R&D and Tech Ops | Tax (F) | −21,423 | $22.22 | -$476.0K | EDGAR |
| 2026-07-29 | Michael Severino | Chief Executive Officer | Award (A) | +756,104 | — | EDGAR | |
| 2026-06-05 | Richard Barry | Director | Award (A) | +16,875 | — | EDGAR | |
| 2026-06-05 | Michael Andrew Chambers | Director | Award (A) | +16,875 | — | EDGAR | |
| 2026-06-05 | Claude Nicaise | Director | Award (A) | +16,875 | — | EDGAR | |
| 2026-06-05 | Deirdre P Connelly | Director | Award (A) | +16,875 | — | EDGAR | |
| 2026-06-05 | M Kathleen Behrens | Director | Award (A) | +16,875 | — | EDGAR | |
| 2026-06-05 | Hans Lennart Rudolf Wigzell | Director | Award (A) | +16,875 | — | EDGAR | |
| 2026-06-05 | Stephen Mayo | Director | Award (A) | +16,875 | — | EDGAR | |
| 2026-06-05 | Kathryn Jean Boor | Director | Award (A) | +16,875 | — | EDGAR | |
| 2026-03-13 | Cristin Rothfuss | EVP, General Counsel | Tax (F) | −974 | $17.03 | -$16.6K | EDGAR |
| 2026-03-13 | Stephen Mayo | Director | Sell (S) | −7,239 | $17.02 | -$123.2K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
SRPT Insider Holdings
16 insiders · @ $17.73
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Richard Barry | Director | 2,993,542 | $53.08M | -$12.11M | 23 | 2026-06-05 |
| 2 | Michael Severino | Chief Executive Officer | 756,104 | $13.41M | $0 | 1 | 2026-07-29 |
| 3 | Michael Andrew Chambers | Director | 504,027 | $8.94M | $23.27M | 13 | 2026-06-05 |
| 4 | Douglas S Ingram | Chief Executive Officer | 440,307 | $7.81M | $14.02M | 13 | 2025-12-09 |
| 5 | M Kathleen Behrens | Director | 224,357 | $3.98M | $193.3K | 28 | 2026-06-05 |
| 6 | Louise Rodino-Klapac | President, R&D and Tech Ops | 203,900 | $3.62M | $299.9K | 30 | 2026-09-08 |
| 7 | Ian Michael Estepan | Chief Operating Officer | 177,184 | $3.14M | -$1.27M | 30 | 2026-09-08 |
| 8 | Ryan Ho-Yan Wong | Chief Financial Officer | 121,792 | $2.16M | $0 | 7 | 2026-09-08 |
| 9 | Cristin Rothfuss | EVP, General Counsel | 115,519 | $2.05M | $0 | 11 | 2026-09-08 |
| 10 | Claude Nicaise | Director | 48,407 | $858.3K | -$248.2K | 14 | 2026-06-05 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
SRPT Board & Officers
As of SEC filings through Sep 8, 2026Directors 10
- M Kathleen Behrens · since Mar 31, 2009
- Hans Lennart Rudolf Wigzell · since Jun 7, 2010
- Claude Nicaise · since Jun 2, 2015
- Richard Barry · since Jun 2, 2015
- Douglas S Ingram · since Jun 26, 2017
- Stephen Mayo · since Nov 16, 2021
- Kathryn Jean Boor · since Jun 2, 2022
- Michael Andrew Chambers · since Jun 2, 2022
- Deirdre P Connelly · since Sep 12, 2024
- Michael Severino · since Jul 28, 2026
Officers 5
- Michael Severino · Chief Executive Officer · since Jul 28, 2026
- Louise Rodino-Klapac · President, R&D and Tech Ops · listed since Aug 2025
- Ryan Ho-Yan Wong · Chief Financial Officer · since Jul 16, 2025
- Ian Michael Estepan · Chief Operating Officer · listed since Aug 2025
- Cristin Rothfuss · EVP, General Counsel · since Nov 26, 2024
Changes in the last 10 years (39)
| Jul 28, 2026 | Michael Severino became a director |
| Jul 28, 2026 | Michael Severino became Chief Executive Officer |
| Feb 25, 2026 | The company announced the departure of Douglas S Ingram as President & CEO in an SEC filing |
| Aug 12, 2025 | The company announced the departure of Bilal Arif as Chief Tech Ops Officer in an SEC filing |
| Aug 6, 2025 | Louise Rodino-Klapac listed as President, R&D and Tech Ops (previously Head of R&D, CSO) in SEC filings |
| Aug 6, 2025 | Ian Michael Estepan listed as Chief Operating Officer (previously Chief Financial Officer) in SEC filings |
| Jul 16, 2025 | Ryan Ho-Yan Wong became Chief Financial Officer |
| Nov 26, 2024 | Cristin Rothfuss became EVP, General Counsel |
| Sep 12, 2024 | Deirdre P Connelly became a director |
| Apr 24, 2024 | Dallan Murray became Chief Customer Officer |
| Jun 5, 2023 | Ryan Edward Brown listed as EVP, General Counsel (previously SVP, General Counsel) in SEC filings |
| Dec 31, 2022 | Bilal Arif became Chief Tech Ops Officer |
| Oct 31, 2022 | The company announced the departure of William Ciambrone as EVP in an SEC filing |
| Jun 2, 2022 | Michael Andrew Chambers became a director |
| Jun 2, 2022 | Kathryn Jean Boor became a director |
| Mar 31, 2022 | The company announced the departure of Mary Ann Gray from the board in an SEC filing |
| Nov 29, 2021 | Louise Rodino-Klapac listed as Head of R&D, CSO (previously Chief Scientific Officer) in SEC filings |
| Nov 16, 2021 | Stephen Mayo became a director |
| Feb 19, 2021 | Ryan Edward Brown became SVP, General Counsel |
| Dec 14, 2020 | Louise Rodino-Klapac became Chief Scientific Officer |
| Dec 14, 2020 | Joseph Bratica reported in an SEC filing no longer being Principal Financial Officer |
| Dec 14, 2020 | Ian Michael Estepan became Chief Financial Officer |
| Aug 3, 2020 | Joseph Bratica became Principal Financial Officer |
| Jan 13, 2020 | John C Martin became a director |
| Nov 18, 2019 | William Ciambrone became EVP |
| Mar 4, 2019 | Gilmore Neil O'Neill listed as EVP, R&D & CMO (previously SVP & Chief Medical Officer) in SEC filings |
| Mar 4, 2019 | David T Howton listed as EVP, General Counsel (previously SVP, General Counsel) in SEC filings |
| Mar 4, 2019 | Alexander Cumbo listed as EVP, Chief Commercial Officer (previously SVP, Chief Commercial Officer) in SEC filings |
| Dec 10, 2018 | Mary Ann Gray became a director |
| Jun 7, 2018 | Gilmore Neil O'Neill became SVP & Chief Medical Officer |
| Mar 7, 2018 | Shamim Ruff listed as SVP, Chief Regulatory Affairs (previously SVP, Regulatory Affairs & Qual) in SEC filings |
| Dec 4, 2017 | Michael W Bonney became a director |
| Sep 25, 2017 | Guriqbal S. Basi became SVP, Chief Scientific Officer |
| Jul 21, 2017 | Edward M. MD Kaye no longer listed as President, CEO & CMO in SEC filings |
| Jun 26, 2017 | Douglas S Ingram became a director |
| Jun 26, 2017 | Douglas S Ingram became President & CEO |
| Jun 8, 2017 | Alexander Cumbo listed as SVP, Chief Commercial Officer (previously VP, Head of Commercial) in SEC filings |
| Apr 3, 2017 | Catherine Stehman-Breen became SVP, Chief Medical Officer |
| Mar 14, 2017 | Sandesh Mahatme listed as EVP, CFO & Cbo (previously Senior Vice President, CFO) in SEC filings |
Not reported recently (13)
- Dallan Murray · Last reported as Chief Customer Officer in an SEC filing dated Mar 11, 2025
- Ryan Edward Brown · Last reported as EVP, General Counsel in an SEC filing dated Jun 25, 2024
- Gilmore Neil O'Neill · Last reported as EVP, R&D & CMO in an SEC filing dated Mar 10, 2021
- John C Martin · Last reported as a director in an SEC filing dated Mar 5, 2021
- Sandesh Mahatme · Last reported as EVP, CFO & Cbo in an SEC filing dated Jul 9, 2020
- David T Howton · Last reported as EVP, General Counsel in an SEC filing dated Jun 22, 2020
- Alexander Cumbo · Last reported as EVP, Chief Commercial Officer in an SEC filing dated Feb 28, 2020
- Michael W Bonney · Last reported as a director in an SEC filing dated Feb 28, 2020
- Shamim Ruff · Last reported as SVP, Chief Regulatory Affairs in an SEC filing dated May 24, 2018
- Guriqbal S. Basi · Last reported as SVP, Chief Scientific Officer in an SEC filing dated Mar 7, 2018
- Edward M. MD Kaye · Last reported as a director in an SEC filing dated Aug 7, 2017
- Catherine Stehman-Breen · Last reported as SVP, Chief Medical Officer in an SEC filing dated Apr 5, 2017
- Jean-Paul Kress · Last reported as a director in an SEC filing dated Mar 14, 2017
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
SRPT Proposed Insider Sales (Form 144)
Latest: 2026-03-12
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
0 filings
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-03-12 | STEPHEN MAYO | Director | 7,239 | $123.2K | 2026-03-12 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2025-12-16 | IAN M ESTEPAN | Officer | 13,187 | $294.1K | 2025-12-16 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2025-03-12 | Nicaise Claude | Director | 2,491 | $248.2K | 2025-03-12 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2024-12-12 | Wigzell Hans Lennart Rudolf | Director | 10,500 | $1.31M | 2024-12-12 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2024-12-05 | Boor Kathryn Jean | Director | 1,636 | $205.4K | 2024-12-05 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2024-08-30 | Estepan Ian Michael | Officer | 5,985 | $822.1K | 2024-08-30 | MORGAN STANLEY SMITH BARNEY LLC … | — | EDGAR |
| 2024-06-25 | BILAL ARIF | Officer | 3,898 | $638.7K | 2024-06-25 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2024-06-25 | RYAN BROWN | Officer | 38,957 | $6.38M | 2024-06-25 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2024-06-24 | BILAL ARIF | Officer | 7,859 | $1.26M | 2024-06-24 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2024-03-11 | Boor Kathryn Jean | Director | 761 | $93.5K | 2024-03-11 | MORGAN STANLEY SMITH BARNEY LLC … | — | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
Recent SEC Filings
Latest: 2026-11-05
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
| Filing Date | Event | Link |
|---|---|---|
| 2026-11-05 | Earnings results | EDGAR |
| 2026-09-23 | Material agreement | EDGAR |
| 2026-08-05 | Earnings results | EDGAR |
| 2026-07-27 | Director or officer change · Regulation FD disclosure | EDGAR |
| 2026-06-04 | Director or officer change · Shareholder vote results | EDGAR |
| 2026-05-06 | Earnings results | EDGAR |
| 2026-02-25 | Earnings results | EDGAR |
| 2026-02-25 | Director or officer change | EDGAR |
| 2026-01-12 | Earnings results | EDGAR |
| 2025-12-19 | Material agreement · New debt obligation | EDGAR |
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
| Filing Date | Accession | Link |
|---|---|---|
| 2026-03-02 | 0001193125-26-084144 | EDGAR |
| 2025-02-28 | 0000950170-25-029973 | EDGAR |
| 2024-02-28 | 0000950170-24-022036 | EDGAR |
| 2023-02-28 | 0000950170-23-005062 | EDGAR |
| 2022-03-01 | 0000950170-22-002517 | EDGAR |
| 2021-03-01 | 0001564590-21-009835 | EDGAR |
| 2020-02-26 | 0001564590-20-006769 | EDGAR |
| 2019-02-28 | 0001564590-19-005170 | EDGAR |
| 2018-03-01 | 0001564590-18-004107 | EDGAR |
| 2017-02-28 | 0001564590-17-002842 | EDGAR |
Quarterly report — unaudited financials and MD&A. Filed 40–45 days after each of the first three fiscal quarters.
| Filing Date | Accession | Link |
|---|---|---|
| 2026-11-05 | 0001193125-26-449721 | EDGAR |
| 2026-08-05 | 0001193125-26-335003 | EDGAR |
| 2026-05-06 | 0001193125-26-208893 | EDGAR |
| 2025-11-06 | 0001193125-25-269436 | EDGAR |
| 2025-08-06 | 0000950170-25-103971 | EDGAR |
| 2025-05-06 | 0000950170-25-064412 | EDGAR |
| 2024-11-06 | 0000950170-24-122239 | EDGAR |
| 2024-08-07 | 0000950170-24-092720 | EDGAR |
| 2024-05-01 | 0000950170-24-051234 | EDGAR |
| 2023-11-01 | 0000950170-23-057414 | EDGAR |
ETF Holders
112 ETFs hold SRPT
25 shown · $504.10M total exposure · 0.11% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | IJR iShares Core S&P Small-Cap ETF | iShares (BlackRock) | 0.11% | $113.9M | $103.8B | 2026-11-06 |
| 2 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $58.4M | — | 2026-09-30 |
| 3 | XBI State Street® SPDR® S&P® Biotech ETF | SPDR (State Street) | 0.54% | $53.8M | $10.0B | 2026-11-05 |
| 4 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.06% | $47.9M | $76.6B | 2026-11-06 |
| 5 | VB Vanguard Morningstar Small-Cap ETF | Vanguard | 0.02% | $41.2M | — | 2026-09-30 |
| 6 | VBK Vanguard Morningstar Small-Cap Growth ETF | Vanguard | 0.05% | $22.9M | — | 2026-09-30 |
| 7 | VXF Vanguard Extended Market ETF | Vanguard | 0.02% | $21.7M | — | 2026-09-30 |
| 8 | SPSM State Street® SPDR® Portfolio S&P 600™ Small Cap ETF | SPDR (State Street) | 0.11% | $16.9M | $15.7B | 2026-11-05 |
| 9 | IWN iShares Russell 2000 Value ETF | iShares (BlackRock) | 0.12% | $16.4M | $13.9B | 2026-11-06 |
| 10 | IBB iShares Biotechnology ETF | iShares (BlackRock) | 0.12% | $13.6M | $11.1B | 2026-11-06 |
| 11 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.06% | $11.0M | — | 2026-09-30 |
| 12 | PBE Invesco Biotechnology & Genome ETF | Invesco | 2.52% | $10.8M | — | 2026-11-05 |
| 13 | SCHA Schwab U.S. Small-Cap ETF | Nport | 0.05% | $10.6M | — | 2026-08-31 |
| 14 | IJT iShares S&P Small-Cap 600 Growth ETF | iShares (BlackRock) | 0.14% | $10.4M | $7.3B | 2026-11-06 |
| 15 | FESM Fidelity Enhanced Small Cap Core ETF | Fidelity | 0.11% | $7.4M | $6.6B | 2026-11-05 |
| 16 | VIOO Vanguard S&P Small-Cap 600 ETF | Vanguard | 0.11% | $6.8M | — | 2026-09-30 |
| 17 | SLYG State Street® SPDR® S&P 600™ Small Cap Growth ETF | SPDR (State Street) | 0.14% | $6.4M | $4.6B | 2026-11-05 |
| 18 | IJS iShares S&P Small-Cap 600 Value ETF | iShares (BlackRock) | 0.08% | $6.1M | $7.5B | 2026-11-06 |
| 19 | VHT Vanguard Health Care ETF | Vanguard | 0.02% | $5.4M | — | 2026-09-30 |
| 20 | DFAC Dimensional US Core Equity 2 ETF | Dimensional | 0.01% | $5.2M | — | 2026-11-05 |
| 21 | DFAS Dimensional US Small Cap ETF | Dimensional | 0.01% | $4.2M | — | 2026-11-05 |
| 22 | SLYV State Street® SPDR® S&P 600™ Small Cap Value ETF | SPDR (State Street) | 0.08% | $3.9M | $4.9B | 2026-11-05 |
| 23 | DFMC Dimensional US Micro Cap ETF | Dimensional | 0.04% | $3.3M | — | 2026-11-05 |
| 24 | EES WisdomTree U.S. SmallCap Fund | Nport | 0.40% | $2.9M | — | 2026-06-30 |
| 25 | MNVT Moonvest ETF | Nport | 4.05% | $2.8M | — | 2026-07-31 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-1.73
TTM Revenue
$1.97B
TTM Net Income
$-136.72M
TTM Op. Cash Flow
$111.01M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q2 '26 | 2026-06-30 | $401.25M | $-4.89M | $-0.05 | $197.07M |
| Q1 '26 | 2026-03-31 | $730.80M | $330.96M | $2.88 | $-202.68M |
| Q4 '25 | 2025-12-31 | $442.93M | $-282.85M | $-2.76 | $131.21M |
| Q3 '25 | 2025-09-30 | $399.36M | $-179.95M | $-1.80 | $-14.59M |
| Q2 '25 | 2025-06-30 | $611.09M | $196.89M | $1.89 | $261.34M |
| Q1 '25 | 2025-03-31 | $744.86M | $-447.51M | $-4.60 | $-583.44M |
| Q4 '24 | 2024-12-31 | $658.41M | $159.05M | $1.56 | $92.05M |
| Q3 '24 | 2024-09-30 | $467.17M | $33.61M | $0.34 | $-70.70M |
| Q2 '24 | 2024-06-30 | $362.93M | $6.46M | $0.07 | $14.94M |
| Q1 '24 | 2024-03-31 | $413.46M | $36.12M | $0.37 | $-242.08M |
| Q4 '23 | 2023-12-31 | $396.78M | $45.66M | $0.76 | $-54.66M |
| Q3 '23 | 2023-09-30 | $331.82M | $-40.94M | $-0.46 | $-114.71M |
Q2 2026 • period ending 2026-06-30 • filed 2026-08-05
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
1.24
P/S
0.96
EV/EBITDA
—
EV/Sales
1.10
ROE
-8.9%
ROA
-4.3%
Div Yield
0.00%
FCF Yield
5.84%
Debt/Equity
0.55
Current Ratio
—
Market Cap
$1.90B
as of 2026-11-09
SRPT vs Peers
Related companies, largest first| Company | Market cap | P/E | Revenue growth | YTD | IV rank |
|---|---|---|---|---|---|
| GILD Gilead Sciences Inc | $207.0B | — | +6.5% | +39.4% | 49 |
| VRTX Vertex Pharmaceuticals Inc | $138.7B | 35.4 | +10.5% | +21.6% | 63 |
| MRNA Moderna, Inc. Common Stock | $101.5B | — | −27.6% | +804.8% | 51 |
| NTRA Natera, Inc. Common Stock | $45.1B | — | +36.6% | +39.5% | 44 |
| BIIB Biogen Inc. Common Stock | $36.7B | 110.3 | +2.3% | +45.1% | 100 |
| NBIX Neurocrine Biosciences Inc | $16.7B | 25.0 | +38.0% | +19.7% | 30 |
| PTCT PTC Therapeutics, Inc. | $5.5B | — | −35.1% | −15.2% | 11 |
| TMDX TransMedics Group, Inc. Common Stock | $3.1B | 24.5 | +25.8% | −22.9% | 18 |
| SRPT Sarepta Therapeutics,, Inc. Common Stock | $1.9B | — | −20.4% | −16.8% | 36 |
| Peer median | $40.9B | 30.2 | +8.5% | +30.5% | 46 |
P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
22.33M
SI % of Float
22.73%
Days to Cover
7.46
Short Vol Ratio
47.8%
Free Float
98.25M
Float %
93.0%
Short interest 2026-10-15 • Short volume 2026-11-06 • Float 2026-08-14